qrt pcr roche lightcycler technology Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Roche qrt pcr roche lightcycler technology
    ASPP2 mRNA expression in acute leukemia. <t>qRT-PCR</t> based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.
    Qrt Pcr Roche Lightcycler Technology, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/qrt pcr roche lightcycler technology/product/Roche
    Average 86 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    qrt pcr roche lightcycler technology - by Bioz Stars, 2020-04
    86/100 stars
      Buy from Supplier

    99
    Thermo Fisher qrt pcr
    ASPP2 mRNA expression in acute leukemia. <t>qRT-PCR</t> based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.
    Qrt Pcr, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 16881 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/qrt pcr/product/Thermo Fisher
    Average 99 stars, based on 16881 article reviews
    Price from $9.99 to $1999.99
    qrt pcr - by Bioz Stars, 2020-04
    99/100 stars
      Buy from Supplier

    99
    Roche real time pcr qrt pcr
    Colonic CCL25 Expression under Non- and Pro-Inflammatory Conditions. CCL25 protein expression was determined by western blots post-immunoprecipitation, I.P. [A], probing for CCL25 in tissue lysates of resected terminal ileum/small bowel (SB), large bowel afflicted with ulcerative colitis (UC) and non-inflamed colon (NC). Band sizes in keeping with dimeric CCL25 are illustrated for samples probed following I.P. (+), the paired cleared lysate (−), and β-actin (housekeeping; cleared lysates only). Membranes bearing NC samples were subject to greater exposure times given the relatively low abundance/absence of CCL25 under non-inflammatory conditions and are therefore shown as a separate group. Differential expression of CCL25 in tissue samples was confirmed by ELISA [B]. Correlation with inflammatory burden was assessed in mucosal biopsy samples obtained during routine, surveillance colonoscopy ( n = 37) by <t>qRT-PCR.</t> Given that CCL25 gene expression was not detectable in non-inflamed colon (control), data are presented relative to GUS-β (housekeeping gene) across endoscopic Mayo severity scores [C] and in correlation with TNFα expression [D]. Asterisks are indicative of statistically significant differences.
    Real Time Pcr Qrt Pcr, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 680 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/real time pcr qrt pcr/product/Roche
    Average 99 stars, based on 680 article reviews
    Price from $9.99 to $1999.99
    real time pcr qrt pcr - by Bioz Stars, 2020-04
    99/100 stars
      Buy from Supplier

    Image Search Results


    ASPP2 mRNA expression in acute leukemia. qRT-PCR based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.

    Journal: PLoS ONE

    Article Title: Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure

    doi: 10.1371/journal.pone.0080193

    Figure Lengend Snippet: ASPP2 mRNA expression in acute leukemia. qRT-PCR based mRNA expression levels are displayed after normalizing to a healthy blood donor (set as 1) on a logarithmic scale. Cohort analysis reveals significant lower ASPP2 levels for an acute leukemia population compared to a healthy peripheral blood and bone marrow donor cohort (A). Comparison of prognostic risk groups confirms lower ASPP2 expression levels for the good-risk as well as higher-risk cohort when compared to a healthy donor population – whereas attenuated ASPP2 expression levels are more pronounced and statistically significantly different for the higher-risk cohort (B). Analysis of therapy responders (i.e. achievement of complete remission after one cycle of induction chemotherapy) demonstrates significantly lower ASPP2 levels for the therapy-failure population when compared to the responder cohort (including good-/higher-risk pts.) (C). ROC curve analysis defining the ideal threshold to distinguish a definite non-responding sub-population is shown in figure 1D (i.e. patients with attenuated ASPP2 expression levels ≤0.8 are likely not to respond to induction chemotherapy (with no single falsely positive tested patient at this threshold). P-values are provided as indicated by an asterix. Patient characteristics, including definitions of the prognostic risk groups, are summarized in Table 1 and 2.

    Article Snippet: ASPP2 mRNA expression levels, relative to GAPD as the housekeeping gene, were determined by qRT-PCR Roche® LightCycler Technology (Roche, Basel, Switzerland).

    Techniques: Expressing, Quantitative RT-PCR

    Colonic CCL25 Expression under Non- and Pro-Inflammatory Conditions. CCL25 protein expression was determined by western blots post-immunoprecipitation, I.P. [A], probing for CCL25 in tissue lysates of resected terminal ileum/small bowel (SB), large bowel afflicted with ulcerative colitis (UC) and non-inflamed colon (NC). Band sizes in keeping with dimeric CCL25 are illustrated for samples probed following I.P. (+), the paired cleared lysate (−), and β-actin (housekeeping; cleared lysates only). Membranes bearing NC samples were subject to greater exposure times given the relatively low abundance/absence of CCL25 under non-inflammatory conditions and are therefore shown as a separate group. Differential expression of CCL25 in tissue samples was confirmed by ELISA [B]. Correlation with inflammatory burden was assessed in mucosal biopsy samples obtained during routine, surveillance colonoscopy ( n = 37) by qRT-PCR. Given that CCL25 gene expression was not detectable in non-inflamed colon (control), data are presented relative to GUS-β (housekeeping gene) across endoscopic Mayo severity scores [C] and in correlation with TNFα expression [D]. Asterisks are indicative of statistically significant differences.

    Journal: Journal of Autoimmunity

    Article Title: Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity

    doi: 10.1016/j.jaut.2016.01.001

    Figure Lengend Snippet: Colonic CCL25 Expression under Non- and Pro-Inflammatory Conditions. CCL25 protein expression was determined by western blots post-immunoprecipitation, I.P. [A], probing for CCL25 in tissue lysates of resected terminal ileum/small bowel (SB), large bowel afflicted with ulcerative colitis (UC) and non-inflamed colon (NC). Band sizes in keeping with dimeric CCL25 are illustrated for samples probed following I.P. (+), the paired cleared lysate (−), and β-actin (housekeeping; cleared lysates only). Membranes bearing NC samples were subject to greater exposure times given the relatively low abundance/absence of CCL25 under non-inflammatory conditions and are therefore shown as a separate group. Differential expression of CCL25 in tissue samples was confirmed by ELISA [B]. Correlation with inflammatory burden was assessed in mucosal biopsy samples obtained during routine, surveillance colonoscopy ( n = 37) by qRT-PCR. Given that CCL25 gene expression was not detectable in non-inflamed colon (control), data are presented relative to GUS-β (housekeeping gene) across endoscopic Mayo severity scores [C] and in correlation with TNFα expression [D]. Asterisks are indicative of statistically significant differences.

    Article Snippet: Differences in target mRNA expression between UC and NC was determined in triplicate for each sample by quantitative real-time PCR (qRT-PCR) (Roche Lightcycler 480; TaqMan Assay Mix, Life Technologies).

    Techniques: Expressing, Western Blot, Immunoprecipitation, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR